Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe

Andrea De Luca; David Dunn; Maurizio Zazzi; Ricardo Camacho; Carlo Torti; Iuri Fanti; Rolf Kaiser; Anders Sönnerborg; Francisco M. Codoñer; Kristel Van Laethem; Anne Mieke Vandamme; Loveleen Bansi; Valeria Ghisetti; David A M C Van De Vijver; David Asboe; Mattia C F Prosperi; Simona Di Giambenedetto

doi:10.1093/infdis/jit017

Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe

Andrea De Luca, David Dunn, Maurizio Zazzi, Ricardo Camacho, Carlo Torti, Iuri Fanti, Rolf Kaiser, Anders Sönnerborg, Francisco M. Codoñer, Kristel Van Laethem, Anne Mieke Vandamme, Loveleen Bansi, Valeria Ghisetti, David A M C Van De Vijver, David Asboe, Mattia C F Prosperi, Simona Di Giambenedetto

Research output: Contribution to journal › Article › peer-review

Abstract

HIV-1 drug resistance represents a major obstacle to infection and disease control. This retrospective study analyzes trends and determinants of resistance in antiretroviral treatment (ART)-exposed individuals across 7 countries in Europe. Of 20 323 cases, 80% carried at least one resistance mutation: these declined from 81% in 1997 to 71% in 2008. Predicted extensive 3-class resistance was rare (3.2% considering the cumulative genotype) and peaked at 4.5% in 2005, decreasing thereafter. The proportion of cases exhausting available drug options dropped from 32% in 2000 to 1% in 2008. Reduced risk of resistance over calendar years was confirmed by multivariable analysis. © 2013 The Author.

Original language	English
Pages (from-to)	1216-1220
Number of pages	4
Journal	Journal of Infectious Diseases
Volume	207
Issue number	8
DOIs	https://doi.org/10.1093/infdis/jit017
Publication status	Published - 15 Apr 2013

Keywords

antiretroviral therapy
drug resistance
epidemiology
genotyping
HIV-1

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/infdis/jit017

Cite this

De Luca, A., Dunn, D., Zazzi, M., Camacho, R., Torti, C., Fanti, I., Kaiser, R., Sönnerborg, A., Codoñer, F. M., Van Laethem, K., Vandamme, A. M., Bansi, L., Ghisetti, V., Van De Vijver, D. A. M. C., Asboe, D., Prosperi, M. C. F., & Di Giambenedetto, S. (2013). Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. Journal of Infectious Diseases, 207(8), 1216-1220. https://doi.org/10.1093/infdis/jit017

@article{7d0eec0eb00f434db184891ffd4edb66,

title = "Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe",

abstract = "HIV-1 drug resistance represents a major obstacle to infection and disease control. This retrospective study analyzes trends and determinants of resistance in antiretroviral treatment (ART)-exposed individuals across 7 countries in Europe. Of 20 323 cases, 80% carried at least one resistance mutation: these declined from 81% in 1997 to 71% in 2008. Predicted extensive 3-class resistance was rare (3.2% considering the cumulative genotype) and peaked at 4.5% in 2005, decreasing thereafter. The proportion of cases exhausting available drug options dropped from 32% in 2000 to 1% in 2008. Reduced risk of resistance over calendar years was confirmed by multivariable analysis. {\textcopyright} 2013 The Author.",

keywords = "antiretroviral therapy, drug resistance, epidemiology, genotyping, HIV-1",

author = "{De Luca}, Andrea and David Dunn and Maurizio Zazzi and Ricardo Camacho and Carlo Torti and Iuri Fanti and Rolf Kaiser and Anders S{\"o}nnerborg and Codo{\~n}er, {Francisco M.} and {Van Laethem}, Kristel and Vandamme, {Anne Mieke} and Loveleen Bansi and Valeria Ghisetti and {Van De Vijver}, {David A M C} and David Asboe and Prosperi, {Mattia C F} and {Di Giambenedetto}, Simona",

year = "2013",

month = apr,

day = "15",

doi = "10.1093/infdis/jit017",

language = "English",

volume = "207",

pages = "1216--1220",

journal = "Journal of Infectious Diseases",

issn = "1537-6613",

publisher = "Oxford University Press ",

number = "8",

}

De Luca, A, Dunn, D, Zazzi, M, Camacho, R, Torti, C, Fanti, I, Kaiser, R, Sönnerborg, A, Codoñer, FM, Van Laethem, K, Vandamme, AM, Bansi, L, Ghisetti, V, Van De Vijver, DAMC, Asboe, D, Prosperi, MCF & Di Giambenedetto, S 2013, 'Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe', Journal of Infectious Diseases, vol. 207, no. 8, pp. 1216-1220. https://doi.org/10.1093/infdis/jit017

TY - JOUR

T1 - Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe

AU - De Luca, Andrea

AU - Dunn, David

AU - Zazzi, Maurizio

AU - Camacho, Ricardo

AU - Torti, Carlo

AU - Fanti, Iuri

AU - Kaiser, Rolf

AU - Sönnerborg, Anders

AU - Codoñer, Francisco M.

AU - Van Laethem, Kristel

AU - Vandamme, Anne Mieke

AU - Bansi, Loveleen

AU - Ghisetti, Valeria

AU - Van De Vijver, David A M C

AU - Asboe, David

AU - Prosperi, Mattia C F

AU - Di Giambenedetto, Simona

PY - 2013/4/15

Y1 - 2013/4/15

N2 - HIV-1 drug resistance represents a major obstacle to infection and disease control. This retrospective study analyzes trends and determinants of resistance in antiretroviral treatment (ART)-exposed individuals across 7 countries in Europe. Of 20 323 cases, 80% carried at least one resistance mutation: these declined from 81% in 1997 to 71% in 2008. Predicted extensive 3-class resistance was rare (3.2% considering the cumulative genotype) and peaked at 4.5% in 2005, decreasing thereafter. The proportion of cases exhausting available drug options dropped from 32% in 2000 to 1% in 2008. Reduced risk of resistance over calendar years was confirmed by multivariable analysis. © 2013 The Author.

AB - HIV-1 drug resistance represents a major obstacle to infection and disease control. This retrospective study analyzes trends and determinants of resistance in antiretroviral treatment (ART)-exposed individuals across 7 countries in Europe. Of 20 323 cases, 80% carried at least one resistance mutation: these declined from 81% in 1997 to 71% in 2008. Predicted extensive 3-class resistance was rare (3.2% considering the cumulative genotype) and peaked at 4.5% in 2005, decreasing thereafter. The proportion of cases exhausting available drug options dropped from 32% in 2000 to 1% in 2008. Reduced risk of resistance over calendar years was confirmed by multivariable analysis. © 2013 The Author.

KW - antiretroviral therapy

KW - drug resistance

KW - epidemiology

KW - genotyping

KW - HIV-1

U2 - 10.1093/infdis/jit017

DO - 10.1093/infdis/jit017

M3 - Article

SN - 1537-6613

VL - 207

SP - 1216

EP - 1220

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 8

ER -

Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this